OCTO Home

---

Breaking News

AspECT

The AspECT recruitment period has been extended to 31st January 2009. There are only 195 patients left to recruit to reach our target of 2500.

VICTOR at ESMO 2008 A presentation looking at recurrence rates in VICTOR patients according to COX-2 genotyping has been accepted for presentation at this year’s ESMO conference in Stockholm (12-16 Sep 2008).

SCOT

The number of CT scans mandated by the protocol is currently under review.
Click here for further details about the trial.

---

About OCTO

The Oncology Clinical Trials Office (OCTO) is concerned with the practical application of high-quality clinical research into innovative and effective cancer therapies particularly in the field of gastrointestinal cancer.

OCTO's key aims are to improve both survival rates and the quality of life of cancer patients by contributing to the evidence-base that will underpin cancer services now and in the future; and to bring about major and continuing improvements in the quality of practice in clinical research. These aims will be achieved in partnership with academic-led research communities, with industry and with patients and their carers.

We aspire to put OCTO on a par with the best in the world, and to establish it as a national and international leader in its approach to the integration of research, treatment and care for cancer patients.

OCTO is part of the Clinical Pharmacology Department of Oxford University.